Tanaproget

Tanaproget is an orally effective, selective nonsteroidal progesterone receptor (PR) agonist targeting human PR with an IC50 of 1.7 nM. Tanaproget promotes the interaction between PR receptors and coactivators (such as SRC-1), thereby inhibiting the secretion of matrix metalloproteinases (MMP-3/MMP-7) and reducing endometrial tissue invasion and angiogenesis. Tanaproget can be used for contraception and endometriosis inhibition research[1][2][3].

Product Specifications

CAS Number

[304853-42-7]

Product Name Alternative

NSP-989

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Progesterone Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/tanaproget.html

Purity

99.73

Solubility

DMSO : ≥ 50 mg/mL

Smiles

N#CC1=CC=C(C2=CC=C(NC(OC3(C)C)=S)C3=C2)N1C

Molecular Formula

C16H15N3OS

Molecular Weight

297.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Bruner-Tran KL, et al. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrin.|[2]Zhang Z, et al. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem. 2005 Aug 5;280 (31) :28468-75.|[3]Bapst JL, et al. Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception. 2006 Nov;74 (5) :414-8.